Author Affiliations: Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York (Dr Wang and Mr Burnett); Henry Ford Hospital, Detroit, Michigan (Dr Lim).
Oxybenzone, an organic UV-B and short-wave UV-A filter, has been available for over 40 years1; it is widely used in sunscreens and other consumer products in the United States.2 The Centers for Disease Control and Prevention has estimated the prevalence of oxybenzone exposure in the general US population to be 96.8%.3 In the past few years, oxybenzone has received increasing attention as a potentially harmful compound. Initial concerns arose when a report demonstrated systemic absorption of oxybenzone in humans at a rate of 1% to 2% after topical application.4 Similar or higher rates of cutaneous absorption in human subjects have been observed.5- 9 The potential for biological effects, however, were first published in a study by Schlumpf et al10 demonstrating uterotropic effects in immature rats after oral administration of oxybenzone; it should be noted that the estrogenic effect detected was less than 1 million-fold of estradiol, the positive control used. Nonetheless, this study has served as the basis for considerable concern among the public.
In assessing the potential for hormonal disruption in humans, we decided to place into perspective the doses of oxybenzone used by Schlumpf et al10 to achieve the 23% increase in uterine size reported in immature rats. We performed 2 calculations: (1) we determined the equivalent amount of sunscreen required to be used topically in humans to achieve the effective cumulative amount of oxybenzone orally administered to immature rats; and (2) we determined the number of years of daily application required to obtain the equivalent levels of oxybenzone that the experimental animals were exposed to.
The oral dose of oxybenzone used by Schlumpf et al10 was 1525 mg/kg/d over a 4-day period. The effective cumulative dose was 6100 mg/kg. To calculate an equivalent amount of sunscreen, the following assumptions were applied to the formula: (1) the weight of an average woman in the United States was assumed to be 74.6 kg11; (2) the absorption rate of topically applied oxybenzone, 10%, was assumed to be approximately 2%4- 9; and (3) the maximum concentration of oxybenzone in sunscreen sold within the United States was assumed to be 6% (wt/vol), or 60 mg/mL.12
([6100 mg of Oxybenzone/kg × 74.6 kg]/2%) × (1 mL of Sunscreen/60 mg of Oxybenzone) = 379 217 mL
We then calculated the number of years of daily application that would be required to apply 379 217 mL of sunscreen under 3 different scenarios:
Scenario 1: 100% body surface area (BSA) coverage at a standard dose of 2 mg/cm2 would require 30 mL (10 950 mL/y with daily application).
Scenario 2: 100% BSA coverage at a dose of 1 mg/cm2 would requires 15 mL (5475 mL/y).
Scenario 3: 25% BSA coverage at a dose of 1 mg/cm2 would require 3.75 mL (1369 mL/y).
For the purposes of this estimation, a generous in-use dose of 1 mg/cm2 was used,13- 16 and it was assumed that coverage of 25% of the human BSA was limited to the face, neck, hands, and arms.17
The numbers of years of daily application required to obtain the equivalent amount of sunscreen under the 3 scenarios are listed in the Table.
Our results indicate that both the application regimens and time periods required to obtain systemic levels of oxybenzone equivalent per unit of body mass are essentially unattainable. Our assumption is more conservative. For instance, the bioavailability of the oxybenzone-containing rat chow used by Schlumpf et al10 may not have been 100%, and we did not take into account the excretion of oxybenzone in humans. In fact, oxybenzone has not been demonstrated to accumulate in the plasma even after several days of topical application.6,9,18 Most relevant to this discussion, however, is that in a human study, oxybenzone did not demonstrate significant endocrine disruption, even with application of a formulation containing 10% oxybenzone.6 In fact, after 40 years of use, we are not aware of any published study that demonstrates acute toxic effects in humans with systemic absorption of oxybenzone.
We do not intend for this exercise to serve as a basis from which to legitimize the extrapolation of data from immature rats to humans. In fact, basic scientific principles regarding the complexities of each respective biological system preclude this. Nonetheless, we hope that this analysis helps to place into perspective the doses reported by the in vivo study from which inappropriate conclusions have been drawn and considerable controversy has developed.
Correspondence: Dr Wang, Dermatology Service, Memorial Sloan-Kettering Cancer Center, 136 Mountain View Blvd, Basking Ridge, NJ 07920 (email@example.com).
Accepted for Publication: November 30, 2010.
Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Wang and Burnett. Acquisition of data: Wang and Burnett. Analysis and interpretation of data: Burnett and Lim. Drafting of the manuscript: Wang and Burnett. Critical revision of the manuscript for important intellectual content: Wang, Burnett, and Lim. Statistical analysis: Lim. Study supervision: Wang and Lim.
Financial Disclosure: None reported.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.